No Data
Ocugen Announces Dosing Completion in Phase 2 ArMaDa Clinical Trial
Ocugen Competes Dosing In Hase 2 ArMaDa Trial Of OCU410
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Avathon Collaborates With Armada to Bring Prescriptive Maintenance, Computer Vision Applications to Remote Industrial Areas
Malaysia Closing Bell on Feb 07 | YTLPOWR Was the Top Gainer of FBM KLCI
Malaysia Closing Bell on Feb 06 | PETGAS Was the Top Gainer of FBM KLCI
GoldminerX : buy as much as you can
FrenchConnection : I would stay away. This stock is now peaking. Above target price.
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
104575069 OP : ouh i see..okay okay?i try survey first cause this is my first time investing..
FrenchConnection FrenchConnection :![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
一笑而过927 : Are you learning to speculate?